These 15-minute presentations offer an intimate setting to have conversations with companies about their products and services. They do not offer CME credits.

Rules and Regulations

Only DDW exhibitors who have secured a booth are eligible to apply for a slot in the Knowledge Hub, subject to availability and adherence to all published guidelines.

Frequently Asked Questions

Please review the Exhibitor Showcase FAQ for additional information.


  • May 3
  • May 4
  • May 5

Sunday, May 3, 2020

DDW Theater 1 (Hall F)Takeda
Moving Treatment Forward in Chronic Idiopathic Constipation (CIC): A New Option
9:30–10:15 a.m.
This program will discuss the efficacy and safety of a new treatment option for adults with CIC, as well as the unmet need, trial design, mechanism of action and dosing/administration.
EndoGastric Solutions
Shaping the Future of GERD: Now is the Time for TIF 2.0 Procedure
11:30 a.m.–12:15 p.m.
The TIF 2.0 procedure using the EsophyX Z+ device is shaping the future of GRED treatment. Innovators will discuss the latest clinical results and how TIF 2.0 can be used in a broader spectrum of patient populations.
Intercept Pharmaceuticals, Inc
Topics in Advanced Fibrosis due to Nonalcoholic Steatohepatitis (NASH)
1:30–2:15 p.m.
Presented by Dr. Mazen Noureddin, MD MHSc., Director Fatty Liver Program, Division of Digestive and Liver Diseases, Comprehensive Transplant Center, Cedars-Sinai® Medical Center, California.
DDW Theater 2 (Hall B1)Allergan/Ironwood
A Proactive Management Approach to IBS‐C and CIC
10:30–11:15 a.m.
IBS-C and CIC, prevalent disorders with chronic and burdensome symptoms, impacts ~40 million Americans and is associated with a high healthcare system cost. Currently, only 16 million seek care, which leaves many untreated and still suffering. Come to a clinical review of a proactive treatment that may help your patients.
Salix Pharmaceuticals
A Closer Look at Diagnosis, Microbial Imbalance and a Short-Term Treatment Option
12:30–1:15 p.m.
Dr. Ali Rezaie, medical director of the GI motility program at Cedars Sinai Medical Center, Los Angeles, will provide a closer look at IBS-D Diagnosis, Microbial Imbalance and discuss a Short-Term Treatment Option.
Mayo Clinic Laboratories
Early-Onset IBD: Genetic Testing and Its Clinical Application
2:30–3:15 p.m.
Identification of early-onset IBD patients may enable tailored treatment and surveillance plans. With over 50 genes implicated in early-onset IBD, genetic testing should be included in the workup of children under the age of six with IBD. Join Mayo Clinic for a discussion of this testing and its clinical application.

Monday, May 4, 2020

DDW Theater 1 (Hall F)STERIS | US Endoscopy
Tips, Techniques and Tools for Advanced Polypectomy
9:30–10:15 a.m.
David L. Diehl, MD, FASGE, director of interventional endoscopy, Geisinger Medical Center, Danville, PA, will lead a discussion around tips, techniques and the latest tools for managing flat polyps, defect closure and electrosurgery applications.
A Proactive Way to Treat IBS-D: Post-Marketing Information and Phase 4 Data
11:30 a.m.–12:15 p.m.
Please join us in a clinical review of exciting Phase 4 data and the latest post-marketing information on a proactive treatment that may help your IBS-D patients. IBS-D is a chronic functional disorder of the GI system that affects approximately 16 million people and 40% suffers remain undiagnosed.
STERIS | US Endoscopy
Avulsion: A novel technique to achieve complete resection of difficult colon polyps
1:30–2:15 p.m.
Gregory Haber, MD, chief of endoscopy and director of advanced therapeutics and innovation, NYU Langone Medical Center, New York, NY, will lead a discussion around the avulsion technique — using hot biopsy forceps to grasp tissue, apply a mechanical force, while applying bursts of a cutting current with minimal cautery.
DDW Theater 2 (Hall B1)Takeda Pharmaceuticals International
Learn about a treatment option for your patients with moderate to severe Crohn’s Disease (CD) who may be ready to begin a biologic therapy
10:30–11:15 a.m.
In this program, expert gastroenterologist Dr. Brian Feagan will discuss the mechanism of action and clinical profile of a therapeutic option for adult patients with moderate to severe CD who may be ready for a biologic.
Salix Pharmaceuticals
PLENVU: A Novel Bowel Preparation for Patients to Achieve Successful Cleaning
12:30–1:15 p.m.
Dr. Brooks Cash, chief, Division of Gastroenterology, Hepatology & Nutrition, University of Texas Health Science Center at Houston, will be discussing a novel bowel preparation for patients to achieve successful cleaning.
Targeting Disease Activity in UC on the Journey to Remission
2:30–3:15 p.m.
Join us on a journey to find clinical remission featuring real patients with ulcerative colitis from a clinical trial and highlighting the importance of proper induction and optimizing the patient experience.

Tuesday, May 5, 2020

DDW Theater 1Janssen Biotech, Inc.
Janssen Biotech, Inc. Product Theater Presentation
9:30–10:15 a.m.
Speaker: Anita Afali, MD, MPH, FACG
CDx Diagnostics
CDx Diagnostics Product Theater Presentation
11:30 a.m.–12:15 p.m.
Description will be coming soon.

Related Opportunities

Satellite Symposium

Satellite Symposia

SS provide your organization with a unique opportunity to host educational programs before or after DDW scientific sessions.

Crowd of DDW

In-Conjunction With Meetings

ICWs are meetings and events arranged by exhibitors, third-party planners, educational institutions or other non-profit organizations during DDW.

TSNN 2018 Winner Badge

Reserve Your Booth

Exceed business goals by exposing your company to key decision makers in GI. The Exhibit Hall will be open May 3-5, 2020.